Daré Bioscience received the second $1.0 million tranche of its $2.0 million NIAID grant for DARE-HPV, bolstering non-dilutive funding for the program. The Phase 2 trial has been initiated in approximately 100 women with persistent high-risk HPV, with topline safety and antiviral data expected in 2027.
Daré Bioscience received the second $1.0 million tranche of a NIAID SBIR grant, bringing total NIH funding for DARE-HPV to $2.0 million for non-clinical development from December 2024 through November 2026.
The Phase 2 trial is a randomized, placebo-controlled, double-blind study evaluating DARE-HPV’s safety and antiviral activity in approximately 100 women with persistent high-risk HPV infection over a 21-day dosing period.
The program is also supported by an up to $10 million ARPA-H contract, underscoring Daré’s strategy of leveraging non-dilutive government funding to advance its women’s health pipeline without diluting shareholders.
With no FDA-approved pharmacologic treatments for high-risk HPV, DARE-HPV could address an unmet market of six million U.S. women annually, with topline data expected in 2027 as a key catalyst.
Finviz
Globenewswire
